Epizyme to Present New Tazemetostat Data at the American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) Congress

Company to Host Investor Conference Call Today at 9:30 a.m. EDT

CAMBRIDGE, Mass., May 17, 2018 (GLOBE NEWSWIRE) — Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage company developing novel epigenetic therapies, announced today that new data from two Phase 2 trials of its lead candidate, tazemetostat, a potent, selective, orally available EZH2 inhibitor, will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and the 23rd Congress of the European Hematology Association (EHA) in Stockholm. These presentations, respectively, will highlight the first reported data on tazemetostat in malignant mesothelioma, and provide updated interim data from follicular lymphoma patients enrolled in the company’s Phase 2 non-Hodgkin lymphoma trial.

“We are pleased to have the opportunity to present key tazemetostat data in malignant mesothelioma and follicular lymphoma at two preeminent medical congresses in June,” said Robert Bazemore, president and chief executive officer of Epizyme. “These data reinforce the clinical activity that has been observed across a range of tumors to date, providing further insight into the potential value of tazemetostat therapy in cancer.”

The data will be presented in the ASCO and EHA sessions listed below:

ASCO Poster Discussion Session
Title: Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactivation
Abstract No.: 8515, Poster Board No.: 121
Date: Sunday, June 3, 2018; 8:00 – 11:30 a.m. CDT
Location: Hall A
Poster will also be discussed at the Poster Discussion Session on Sunday, June 3, 2018 from 4:45 – 6:00 p.m. CDT at the Arie Crown Theater.

EHA Oral Presentation
Title: Interim Update from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Abstract No.: S100
Date: Friday, June 15, 2018; 11:30 – 11:45 a.m. CEST
Location: Room A1

Investor Conference Call
Epizyme will host an investor conference call and webcast today at 9:30 a.m. EDT to discuss these upcoming presentations and recent corporate updates. To participate, please dial (877) 844-6886 (domestic) or (970) 315-0315 (international) and refer to conference ID 3058627. A live webcast will be available in the investor section of the company’s website at www.epizyme.com. The webcast will be archived on the website for 60 days.

About the Tazemetostat Clinical Trial Program
Tazemetostat, a first-in-class EZH2 inhibitor, is currently being studied as a monotherapy in ongoing Phase 1 and 2 programs in certain molecularly defined solid tumors, including epithelioid sarcoma and other INI1-negative tumors; both follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) forms of non-Hodgkin lymphoma (NHL); mesothelioma; and combination studies in DLBCL.

About Epizyme, Inc.
Epizyme, Inc. is a clinical-stage biopharmaceutical company committed to rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. Epizyme is broadly developing its lead product candidate, tazemetostat, a first-in-class EZH2 inhibitor, with studies underway in both solid tumors and hematological malignancies, as a monotherapy and combination therapy in relapsed and front-line disease. The company is also developing a novel G9a program with its next development candidate, EZM8266, which is targeting sickle cell disease. By focusing on the genetic drivers of disease, Epizyme’s science seeks to match targeted medicines with the patients who need them. For more information, visit www.epizyme.com.

Cautionary Note on Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for Epizyme, Inc. and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties relating to the company’s ability to resume enrollment in its tazemetostat trials and the timing of such resumption, the impact of the partial clinical hold on the company’s development timelines and the impact of the safety finding on enrollment of patients in ongoing and future trials of tazemetostat following the lifting of the partial clinical hold and the resumption of enrollment; uncertainties inherent in the initiation of future clinical studies and in the availability and timing of data from ongoing clinical studies; whether interim results from a clinical trial will be predictive of the final results of the trial; whether results from preclinical studies or earlier clinical studies will be predictive of the results of future trials; whether results from clinical studies will warrant meetings with regulatory authorities, submissions for regulatory approval or review by governmental authorities under the accelerated approval process; whether Fast Track Designation and Orphan Drug Designations will provide the benefits for which tazemetostat is eligible; expectations for regulatory approvals to conduct trials or to market products; whether the company’s cash resources will be sufficient to fund the company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; other matters that could affect the availability or commercial potential of the company’s therapeutic candidates; and other factors discussed in the “Risk Factors” section of the company’s most recent Form 10-Q filed with the SEC and in the company’s other filings from time to time with the SEC. In addition, the forward-looking statements included in this press release represent the company’s views as of the date hereof and should not be relied upon as representing the company’s views as of any date subsequent to the date hereof. The company anticipates that subsequent events and developments will cause the company’s views to change. However, while the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so.


Erin Graves, Epizyme, Inc.
(617) 500-0615

Jason Fredette, Epizyme, Inc.
(617) 500-0623